Back to search

Article

Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer

2022-06-29

Abstract excerpt

<title>Abstract</title> <p>Anlotinib has been demonstrated to be effective in advanced non-small cell lung cancer (NSCLC) patients. The response stratification of anlotinib remains unclear. In this study, plasma samples from 28 anlotinib-treated NSCLC patients (discovery cohort: 14 responders and 14 non-responders) were subjected to proteomic analysis, and plasma samples from 35 anlotinib-treated NSCLC patients (...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
121fdec6-03bc-54a4-98e3-468341e4dc6c
DOI
10.21203/rs.3.rs-26596/v2
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Screening anlotinib responders via blood-based proteomics in non-small cell lung cancerDOI 10.21203/rs.3.rs-26596/v2
Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd LineSemantic proximity
Serum Proteomic Profile of Advanced NSCLC and Exploration of Efficacy Markers for Anti-Angiogenic DrugsSemantic proximity
Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapySemantic proximity
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinibSemantic proximity
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.Semantic proximity
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.Semantic proximity
Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with AnlotinibSemantic proximity
Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.Semantic proximity
[Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant Gene Mutation in Advanced Lung Adenocarcinoma].Semantic proximity
Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.Semantic proximity
Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cellsSemantic proximity
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)Semantic proximity
Select a neighboring publication to make it the new centre.